Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

计划入组 24 人 · 首次发布于 2009 年 5 月 7 日

Study Evaluating Single Doses of BLI-489 in Healthy Subjects

计划入组 54 人 · 首次发布于 2009 年 1 月 12 日

Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects

计划入组 40 人 · 首次发布于 2009 年 3 月 2 日

TVGN-489

TVGN 960

TVGN 920

IRX Therapeutics, Inc.

United States

Molecular Targeting Technologies, Inc.

United States

Solid Biosciences Inc.

United States

Tevogen's TVGN-489 T Cell Therapy Achieves $9-11 Billion Valuation Following Successful COVID-19 Trial

Tevogen Bio's TVGN 489 Shows Promise in High-Risk COVID-19 Patients

Tevogen Bio Expands TVGN 489 Pipeline to Include Patients 65 and Older, Targeting $1 Billion Launch Year Revenue